Status:
COMPLETED
A Study in Subjects With Retinitis Pigmentosa
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Conditions:
Retinitis Pigmentosa
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of AD...
Eligibility Criteria
Inclusion
- Up to 8 adult patients age 18 or older
- Diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including P23H
- Impairment on Visual Field as determined by perimetry
Exclusion
- Age \< 18 years
- Pregnant
- Previous inflammatory/infectious events involving the eyes
Key Trial Info
Start Date :
July 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 23 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05392179
Start Date
July 14 2022
End Date
June 23 2023
Last Update
April 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Eye Center
Durham, North Carolina, United States, 27710